Open Access Articles- Top Results for NS-11394


File:NS-11394 structure.png
Systematic (IUPAC) name
Clinical data
951650-22-9 7pxY
PubChem CID 16747643
ChemSpider 20578861 7pxN
Chemical data
Formula C23H19N3O
353.416 g/mol
 14pxN (what is this?)  (verify)

NS-11394 is a drug which acts as a subtype-selective positive allosteric modulator at GABAA receptors, with selectivity for the α3 and α5 subtypes.[1][2] It has been researched as an analgesic for use in chronic or neuropathic pain.[3]


  1. Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen EØ, Larsen JS, Ahring PK, Mirza NR (December 2008). "Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics 327 (3): 969–81. PMID 18791060. doi:10.1124/jpet.108.144568. 
  2. Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen EØ, Ahring PK (December 2008). "NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy". The Journal of Pharmacology and Experimental Therapeutics 327 (3): 954–68. PMID 18791063. doi:10.1124/jpet.108.138859. 
  3. Munro G, Ahring PK, Mirza NR (September 2009). "Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets". Trends in Pharmacological Sciences 30 (9): 453–9. PMID 19729210. doi:10.1016/